Genmab | GEN - Gross Profit On Sales


Genmab reported DKK1.07B in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Almirall EUR 429.87M 180.02M Dec/2025
Amarin USD 23.17M 961K Dec/2025
Amgen USD 5.87B 1.02B Mar/2026
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Bayer EUR 8.17B 1.24B Mar/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Demant DKK 8.82B 277M Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Fresenius Medical Care EUR 1.18B 210M Mar/2026
Genmab DKK 1.07B 240M Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
GN Store Nord DKK 2.5B 344M Dec/2025
GRIFOLS EUR 704M 84M Jun/2026
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Insmed USD 356.19M 99.73M Jun/2026
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.07B 104M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
UCB EUR 3.19B 621M Dec/2025